The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, Y.
Right arrow Articles by Herold, K. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, Y.
Right arrow Articles by Herold, K. C.
The Journal of Immunology, 2004, 173: 1399-1405.
Copyright © 2004 by The American Association of Immunologists

Blockade of Late Stages of Autoimmune Diabetes by Inhibition of the Receptor for Advanced Glycation End Products1

Yali Chen*,{dagger}, Shirley ShiDu Yan{dagger}, John Colgan{ddagger}, Hui-Ping Zhang{dagger}, Jeremy Luban{ddagger}, Ann Marie Schmidt{dagger}, David Stern§ and Kevan C. Herold2,*,{dagger}

Naomi Berrie Diabetes Center, Division of Endocrinology, Departments of * Medicine, {dagger} Surgery, and {ddagger} Microbiology, College of Physicians and Surgeons, Columbia University, New York, NY 10032; and § Medical College of Georgia, Augusta, GA 30912

Ligation of the receptor for advanced glycation end products (RAGE) occurs during inflammation. Engagement of RAGE results in enhanced expression of addressins and it is therefore, not surprising that previous studies have shown a role of RAGE/ligand interactions in immune responses including cell/cell contact but the role of RAGE in spontaneous autoimmunity has not been clearly defined. To study the role of RAGE/ligand interactions in autoimmune diabetes, we tested the ability of soluble RAGE, a scavenger of RAGE ligands, in late stages of diabetes development in the NOD mouse-disease transferred with diabetogenic T cells and recurrent disease in NOD/scid recipients of syngeneic islet transplants. RAGE expression was detected on CD4+, CD8+, and B cells from diabetic mice and transferred to NOD/scid recipients. RAGE and its ligand, S100B, were found in the islets of NOD/scid mice that developed diabetes. Treatment of recipient NOD/scid mice with soluble RAGE prevented transfer of diabetes and delayed recurrent disease in syngeneic islet transplants. RAGE blockade was associated with increased expression of IL-10 and TGF-{beta} in the islets from protected mice. RAGE blockade reduced the transfer of disease with enriched T cells, but had no effect when diabetes was transferred with the activated CD4+ T cell clone, BDC2.5. We conclude that RAGE/ligand interactions are involved in the differentiation of T cells to a mature pathogenic phenotype during the late stages of the development of diabetes.




This article has been cited by other articles:


Home page
Ann. N. Y. Acad. Sci.Home page
R. RAMASAMY, S. F. YAN, K. HEROLD, R. CLYNES, and A. M. SCHMIDT
Receptor for Advanced Glycation End Products: Fundamental Roles in the Inflammatory Response: Winding the Way to the Pathogenesis of Endothelial Dysfunction and Atherosclerosis
Ann. N.Y. Acad. Sci., April 1, 2008; 1126(1): 7 - 13.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
K. Hiwatashi, S. Ueno, K. Abeyama, F. Kubo, M. Sakoda, I. Maruyama, M. Hamanoue, S. Natsugoe, and T. Aikou
A Novel Function of the Receptor for Advanced Glycation End-Products (RAGE) in Association with Tumorigenesis and Tumor Differentiation of HCC
Ann. Surg. Oncol., March 1, 2008; 15(3): 923 - 933.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. Moser, D. D. Desai, M. P. Downie, Y. Chen, S. F. Yan, K. Herold, A. M. Schmidt, and R. Clynes
Receptor for Advanced Glycation End Products Expression on T Cells Contributes to Antigen-Specific Cellular Expansion In Vivo
J. Immunol., December 15, 2007; 179(12): 8051 - 8058.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
K. Herold, B. Moser, Y. Chen, S. Zeng, S. F. Yan, R. Ramasamy, J. Emond, R. Clynes, and A. M. Schmidt
Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress
J. Leukoc. Biol., August 1, 2007; 82(2): 204 - 212.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
H. Koyama, T. Shoji, H. Yokoyama, K. Motoyama, K. Mori, S. Fukumoto, M. Emoto, T. Shoji, H. Tamei, H. Matsuki, et al.
Plasma Level of Endogenous Secretory RAGE Is Associated With Components of the Metabolic Syndrome and Atherosclerosis
Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2587 - 2593.
[Abstract] [Full Text] [PDF]


Home page
GlycobiologyHome page
R. Ramasamy, S. J. Vannucci, S. S. D. Yan, K. Herold, S. F. Yan, and A. M. Schmidt
Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation
Glycobiology, July 1, 2005; 15(7): 16R - 28R.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
W. KIM, B. I. HUDSON, B. MOSER, J. GUO, L. L. RONG, Y. LU, W. QU, E. LALLA, S. LERNER, Y. CHEN, et al.
Receptor for Advanced Glycation End Products and Its Ligands: A Journey from the Complications of Diabetes to Its Pathogenesis
Ann. N.Y. Acad. Sci., June 1, 2005; 1043(1): 553 - 561.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
B. I. Hudson, E. Harja, B. Moser, and A. M. Schmidt
Soluble Levels of Receptor for Advanced Glycation Endproducts (sRAGE) and Coronary Artery Disease: The Next C-Reactive Protein?
Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): 879 - 882.
[Full Text] [PDF]


Home page
J. Exp. Med.Home page
G. Cataldegirmen, S. Zeng, N. Feirt, N. Ippagunta, H. Dun, W. Qu, Y. Lu, L. L. Rong, M. A. Hofmann, T. Kislinger, et al.
RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-{alpha} and NF-{kappa}B
J. Exp. Med., February 7, 2005; 201(3): 473 - 484.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.